This study aimed to develop microspheres using water-soluble carriers and surfactants to
improve the solubility, dissolution, and oral bioavailability of rivaroxaban (RXB). RXB-loaded …

The purpose of this study was to investigate the efficacy of hydrophilic polymers in a solid
dispersion formulation in improving the solubility and dissolution rate of rivaroxaban (RXB) …

Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor
Xa, given as monotherapy in the treatment of venous thromboembolism (VTE). It has been …

This study aimed to investigate the use of Sucrose acetate isobutyrate (SAIB) and Glyceryl
monooleate (GMO) as co-formers for creating Cubosomes and SAIB-based nanodispersions …

In this study, chitosan (CS) caged classic liposomes (CLs) and flexible liposomes (FLs) were
developed to enhance the oral bioavailability of rivaroxaban (RVX) in the fasted condition …

Rivaroxaban (RXB), a novel oral anticoagulant that directly inhibits factor Xa, is a poorly
soluble drug belonging to Biopharmaceutics Classification System (BCS) class II. In this …

The purpose of the currents study was to enhance bioavailability of rivaroxaban (RXB) and
reduce the food effect. RXB loaded PLGA nanoparticles (RXB-PLGA-NPs) were prepared by …

In this paper, a novel self-nanoemulsifying drug delivery system (SNEDDS) was used to
improve the oral bioavailability in fasted state and diminish the food effect for rivaroxaban …

Rivaroxaban (RVX), an oral direct factor Xa inhibitor, is being explored as an alternative to
traditional anticoagulans. However, RVX still faces pharmacokinetic limitations and adverse …

Objectives Rivaroxaban (RXB), a novel Xa inhibitor having groundbreaking therapeutic
potential. However, this drug is associated with few limitations, including its …